Latest studies into retatruptide peptide reveal notable possibility for managing weight and type 2 disease. The compound, a dual activator of GLP-1 receptor and GIP receptor, seems to offer enhanced weight loss and blood sugar management compared existing treatments. Additional research efforts are required to fully assess its safety record and lon